PMID- 30588002
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 15
DP  - 2019
TI  - Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and 
      mental status in Chinese patients with CHF.
PG  - 23-31
LID - 10.2147/TCRM.S188123 [doi]
AB  - OBJECTIVE: The objective of the study was to evaluate the dose-related influence 
      of metoprolol on cardiac performance, motor function, quality of life (QoL), and 
      mental status in Chinese patients with chronic heart failure (CHF). PATIENTS AND 
      METHODS: This was a prospectively designed single-center study which enrolled CHF 
      patients with resting heart rate (HR) >80 bpm belonging to the New York Heart 
      Association (NYHA) III/IV functional classification. Patients were initiated with 
      12.5 mg of metoprolol, and every second week, the dose was escalated until the 
      target HR level (60-70 bpm) was achieved during the follow-up at 1st, 3rd, 6th, 
      and 12th months. Patients were divided into two groups depending on the doses 
      administered: 47.5 mg (n=37) and 118.75 mg (n=74), respectively, for comparison 
      in terms of change in cardiac function, motor function, QoL, and mental status. 
      RESULTS: Among the 111 patients with CHF, no significant difference was shown 
      between the two doses administered. Irrespective of the dose, the cardiac 
      performance, motor function, QoL, and anxiety improved and there was an increase 
      in depression, whereas the effect on burnout, calculated as Copenhagen Burnout 
      Inventory (CBI), equally was insignificant throughout the 1-year follow-up period 
      in both the CHF patient groups. CONCLUSION: Lower dose of metoprolol (47.5 mg) is 
      as effective as higher dose (118.75 mg) in Chinese population with CHF to improve 
      the cardiac function, motor function, QoL, and mental status.
FAU - Zhang, Qian
AU  - Zhang Q
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan 650101, People's Republic of China, 
      mengyong76@gmail.com.
FAU - Shu, Qiuhong
AU  - Shu Q
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan 650101, People's Republic of China, 
      mengyong76@gmail.com.
FAU - Wu, Liyong
AU  - Wu L
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan 650101, People's Republic of China, 
      mengyong76@gmail.com.
FAU - Zhang, Ran
AU  - Zhang R
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan 650101, People's Republic of China, 
      mengyong76@gmail.com.
FAU - Meng, Yong
AU  - Meng Y
AD  - Department of Cardiology, The Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan 650101, People's Republic of China, 
      mengyong76@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20181218
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC6302828
OTO - NOTNLM
OT  - ejection fraction
OT  - heart rate
OT  - mental status
OT  - metoprolol
OT  - motor function
OT  - quality of life
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/12/28 06:00
MHDA- 2018/12/28 06:01
PMCR- 2018/12/18
CRDT- 2018/12/28 06:00
PHST- 2018/12/28 06:00 [entrez]
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2018/12/28 06:01 [medline]
PHST- 2018/12/18 00:00 [pmc-release]
AID - tcrm-15-023 [pii]
AID - 10.2147/TCRM.S188123 [doi]
PST - epublish
SO  - Ther Clin Risk Manag. 2018 Dec 18;15:23-31. doi: 10.2147/TCRM.S188123. 
      eCollection 2019.